Connection
Daniel Bowles to Piperazines
This is a "connection" page, showing publications Daniel Bowles has written about Piperazines.
|
|
Connection Strength |
|
|
|
|
|
0.123 |
|
|
|
-
Thienelt CD, Green K, Bowles DW. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today (Barc). 2012 Sep; 48(9):601-13.
Score: 0.089
-
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959.
Score: 0.033